The hypothesis that listening to Mozart’s music may be beneficial for epileptic patients has been investigated in previous studies, yet whether the “Mozart Effect” exists is still controversial. This was the motivation for a meta-analysis in which 147 abstracts were collected, of which 12 articles were included [2]. The particular pieces of music assessed were Mozart’s Sonata for two pianos in D major K448, Mozart’s piano sonata in C major K545, and a set of Mozart’s compositions.
Listening to Mozart, especially when daily, led to a significant reduction in epileptic seizures. Patients experienced a significant reduction versus baseline in seizure frequency during the treatment periods (31.17%; 95% CI 20.70-41.64), in interictal epileptiform discharge (IED) frequency during (28.21%) and after (20.12%) a single stimulation, and after a treatment period (79.29%) when patients listened to the K448 sonata. When the set of Mozart’s compositions was listened to, the reduction in seizure frequency was 66.17% (95% CI 38.99-93.36); there was a significant reduction in IED frequency during (35.51%) and after (37.78%) a single stimulation with K545 sonata.
These results demonstrated that music-based neurostimulation may improve the clinical outcome in epilepsy by reducing the frequency of seizures and IED. Therefore, it may be used as a complementary treatment in epilepsy. Asked about the choice for Mozart’s music, Dr Sesso said that it fulfils some psychological need. Nevertheless, the mechanisms behind the Mozart Effect are poorly understood. Other music may have similar effects, but it may be that Mozart’s sonatas have distinctive rhythmic structures that are particularly suited for epilepsy. This may involve several brain systems, but this would need to be proven.
- Sesso G, et al. Safe and sound: meta-analysing the Mozart effect on epilepsy. ECNP Congress 2020.
- Sesso G & Sicca F. Clin Neurophysiol 2020;131(7):1610-1620.
Posted on
Previous Article
« Combination checkpoint and VEGF inhibitors now first-line treatment for advanced liver cancer Next Article
Early pulmonary rehabilitation post-COVID-19 aids recovery »
« Combination checkpoint and VEGF inhibitors now first-line treatment for advanced liver cancer Next Article
Early pulmonary rehabilitation post-COVID-19 aids recovery »
Table of Contents: ECNP 2020
Featured articles
Psychosis and Schizophrenia
Prognostic tools in the management of clinical high risk for psychosis
Reduced auditory cortex activation during speech perception in patients with schizophrenia
Dementia
Predicting MCI and dementia by assessing worrying about memory
Genomics of vascular dementia and stroke
Bipolar Disorders
Social media and bipolar disorder: a risky combination
How to prevent the onset and first relapse of bipolar disorders?
Seasonal pattern and bipolar disorder
OCD and Depression
Personalised medicine in depression: a realistic way forward?
Heart rate could be a potential biomarker for depression
Listening to Mozart has a beneficial effect on epilepsy
Mental Health
Mental health during the COVID-19 pandemic
Microdosing psychedelics offers perspective but needs further evaluation
The PRISM project: focusing on biological parameters across neuropsychiatric disorders
Smartphone can support personalised medicine in psychiatry
Baby’s heart rate shows stress if their mother is depressed or anxious
Autism and ADHD
Movement computing promising in analysing motor impairment in children with autism spectrum disorder
Screening with ADHD Self-Report accurate in girls
No altered fractional anisotropy in ADHD
Role of the Microbiome
Micronutrient supplementation as treatment for psychiatric symptoms
Substance Abuse
Altered gene expression of endogenous opioid system after alcohol exposure in adolescent rodents
Subgroups in alcohol use disorder based on externalising symptoms
New drugs for alcohol use disorder to focus on combination therapy
Related Articles
November 2, 2020
Predicting MCI and dementia by assessing worrying about memory
March 16, 2021
ACE inhibitors tied to schizophrenia risk
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com